European urology oncology最新文献

{"title":"Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study.","authors":"Laurence Albiges, Marine Gross-Goupil, Philippe Barthélémy, Aristotelis Bamias, Jens Bedke, Axel Bex, Mário Fontes-Sousa, Viktor Grünwald, Bohuslav Melichar, Lisa Pickering, Camillo Porta, Giuseppe Procopio, Sylvie Rottey, Manuela Schmidinger, Cristina Suárez, Guillermo Velasco, Bernard Escudier","doi":"10.1016/j.euo.2025.01.007","DOIUrl":"https://doi.org/10.1016/j.euo.2025.01.007","url":null,"abstract":"<p><strong>Background and objective: </strong>Management of metastatic renal cell carcinoma (mRCC) remains complex despite clinical guidelines. The aim of this Delphi study was to achieve consensus among RCC experts on the definition, diagnosis, and first-line treatments for mRCC.</p><p><strong>Methods: </strong>Between May 2023 and April 2024, 14 experts from ten European countries completed two Delphi rounds of a 51-item questionnaire covering four topics: (1) oligometastatic RCC; (2) first-line treatment for metastatic clear-cell RCC; (3) treatment duration for metastatic clear-cell RCC; and (4) treatment of non-clear-cell RCC. Agreement was scored as absent/poor (<50%), fair (50-74%), or consensus (≥75%).</p><p><strong>Key findings and limitations: </strong>Consensus was reached for 12 of 51 items (24%) in the first round and 25 of 49 items (51%) by the study end. Notably, 79% of experts defined oligometastatic RCC as five or fewer metastases and agreed that it typically does not require immediate systemic treatment. All experts (100%) emphasized the importance of clinical performance status in guiding treatment for metastatic clear-cell RCC, with 86% agreeing on additional factors such as International Society of Urological Pathology grade and sarcomatoid features. Nivolumab plus cabozantinib was favored for patients with brain or bone metastases (93% and 86% agreement, respectively), while there was fair agreement on pembrolizumab plus lenvatinib for patients with liver metastases. In addition, 71% supported stopping immune checkpoint inhibitors after 2 yr, while 86% agreed on the undefined duration of tyrosine kinase inhibitor therapy.</p><p><strong>Conclusions and clinical implications: </strong>This Delphi study offers insights into mRCC management, and highlights the importance of multidisciplinary discussions for this challenging disease.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series","authors":"Ludwige Abancourt ,&nbsp;Muhammad Ali ,&nbsp;Magali Quivrin ,&nbsp;Jennifer Wallet ,&nbsp;Ulrike Schick ,&nbsp;Gianluca Ingrosso ,&nbsp;Stéphane Supiot ,&nbsp;Ciro Franzese ,&nbsp;Marta Scorsetti ,&nbsp;Linda Kerkmeijer ,&nbsp;Andrei Fodor ,&nbsp;Nadia Di Muzio ,&nbsp;Natacha Jousset ,&nbsp;Thomas Boisserie ,&nbsp;Beatrice Detti ,&nbsp;Luca Nicosia ,&nbsp;Filippo Alongi ,&nbsp;Fabio Trippa ,&nbsp;Thomas Leleu ,&nbsp;Loïsse Dessoude ,&nbsp;David Pasquier","doi":"10.1016/j.euo.2025.01.001","DOIUrl":"10.1016/j.euo.2025.01.001","url":null,"abstract":"<div><h3>Background and objective</h3><div>For inoperable patients, stereotactic body radiation therapy (SBRT) is a noninvasive treatment approach for primary renal cell carcinoma (RCC). We aimed to evaluate local control (LC) of primary RCC treated with SBRT.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study involved 16 centers in Australia, France, Italy, and the Netherlands. The primary endpoint was the LC probability, and the secondary endpoints were progression-free survival, overall survival (OS), cumulative incidence of cancer-related deaths, toxicities, and renal function evolution after SBRT.</div></div><div><h3>Key findings and limitations</h3><div>A total of 144 patients, treated between 2008 and 2020, with a median follow-up of 43 mo (interquartile range [IQR], 24.0–81.2), were included. The median age was 76 yr (IQR, 67.0–82.0) and the median tumor size was 4.4 cm (IQR, 3.3–5.6). The median baseline estimated glomerular filtration rate (eGFR) was 60 ml/min/1.73 m². Of the patients, 40% had mild to moderate eGFR (30–60 ml/min). The two main treatment regimens were 42 Gy in three fractions and 26 Gy in one fraction. The LC probability was 98% at 1 yr (95% confidence interval [CI], 94–99) and 96% (95% CI, 92–99) at 5 yr. The median OS was 58 mo and the cumulative incidence of cancer-related deaths was 8% (95% CI, 3–15) at 5 yr. Seventy-one patients (49%) experienced at least one toxicity, including grade 1 in the majority (32%), grade 2 (14%), and grade 3 (1%). Two patients (1%) underwent dialysis (grade 4). The median eGFR loss was –7 ml/min (IQR, –17; 0) at the last follow-up.</div></div><div><h3>Conclusions and clinical implications</h3><div>This large series of primary RCC treated with SBRT demonstrates excellent LC and renal function preservation, and is associated with an acceptable toxicity profile. SBRT is an alternative treatment for inoperable patients.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Pages 774-781"},"PeriodicalIF":8.3,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60","authors":"Francesco Montorsi ,&nbsp;Giorgio Gandaglia ,&nbsp;Francesco Barletta ,&nbsp;Alberto Briganti","doi":"10.1016/j.euo.2025.01.012","DOIUrl":"10.1016/j.euo.2025.01.012","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Page 856"},"PeriodicalIF":8.3,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after ¹⁷⁷Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.","authors":"Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, Ali T Arafa, Laura S Graham, Roman Gulati, Colin C Pritchard, Robert B Montgomery, Michael C Haffner, Peter S Nelson, Evan Y Yu, Jessica E Hawley, Heather H Cheng, George Mo, Delphine L Chen, Emmanuel S Antonarakis, Deepak Kilari, Thomas A Hope, Amir Iravani, Michael T Schweizer","doi":"10.1016/j.euo.2025.01.002","DOIUrl":"10.1016/j.euo.2025.01.002","url":null,"abstract":"<p><strong>Background and objective: </strong>The prostate-specific membrane antigen (PSMA) radioligand ¹⁷⁷Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC and mutations in homologous recombination repair (HRR) pathway genes. Both modalities induce DNA damage and therefore may share mechanisms of resistance. We investigated whether PARPi exposure would reduce the subsequent efficacy of LuPSMA.</p><p><strong>Methods: </strong>This retrospective study included 100 patients with a PARPi-qualifying HRR alteration treated with LuPSMA. Clinical outcomes on LuPSMA, including PSA₅₀ response, PSA progression-free survival (PFS), and overall survival (OS), were compared between those who had not previously received PARPi (PARPi-N) and those who had (PARPi-T). Subgroup analyses were performed for the most frequent HRR alterations (BRCA2 and ATM).</p><p><strong>Key findings and limitations: </strong>PSA₅₀ responses on LuPSMA were similar between PARPi-N (n = 47) and PARPi-T (n = 53), although PSA PFS was longer in the PARPi-N group (9.1 vs 4.8 mo; p = 0.037). Among patients with BRCA2 alterations, the PARPi-N group had a better PSA₅₀ response rate (89% vs 35%; p = 0.009), PSA PFS (14 vs 2.9 mo; p = 0.026), and OS (19 vs 5.3 mo; p = 0.10). PARPi exposure did not influence LuPSMA outcomes among patients with ATM alterations. Limitations include the retrospective design and differences in prior lines of therapy between the groups.</p><p><strong>Conclusions and clinical implications: </strong>PARPi exposure is associated with inferior LuPSMA outcomes, particularly for patients with BRCA2 alterations. These findings suggest potential cross-resistance and underscore the need for prospective studies assessing the optimal sequencing of these agents.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60","authors":"Bertrand Tombal ,&nbsp;Yohann Loriot","doi":"10.1016/j.euo.2025.01.010","DOIUrl":"10.1016/j.euo.2025.01.010","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Page 853"},"PeriodicalIF":8.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey.","authors":"Anna Patrikidou, Christoph Oing, Christos Markellos, Axel Heidenreich, Ricardo Leao, Nicola Nicolai, Joost Boormans, Stefanie Fischer, Christian Fankhauser, Walter Cazzaniga, Patrizia Giannatempo, Daniel Berney, Hendrik Gremmels, Robert Cornes, Florian Janisch, Domenico Di Nardo, Alexandros Papachristofilou, Karim Fizazi, Togrim Tandstad, David Nicol, Robert Huddart","doi":"10.1016/j.euo.2025.01.006","DOIUrl":"https://doi.org/10.1016/j.euo.2025.01.006","url":null,"abstract":"<p><p>The 2021 updated International Germ Cell Cancer Collaborative Group classification for seminomatous germ cell tumours confirmed and refined the original classification, introducing the notion that lactate dehydrogenase (LDH) elevation above 2.5 times the upper limit of normal separates the good-risk prognostic group into two distinct subgroups, with clearly inferior survival outcomes for the high-LDH subgroup. Validation of this prognostic factor has understandably opened the question of the optimal management for patients with high-LDH good-risk seminoma. In the absence of prospective evidence, guideline-recommended management options have not changed. However, there is evidence from the testicular cancer community that management trends might have been influenced by the poor prognosis associated with elevated LDH. The Testicular Cancer Guidelines Panel of the European Association of Urology has undertaken a global survey among oncologists and onco-urologists to document management trends and differences. PATIENT SUMMARY: Levels of an enzyme called LDH (lactate dehydrogenase) can differ among patients with testicular cancer that has good prognosis. Recent evidence shows worse outcomes for patients with higher LDH. This information should be used to update clinical guidelines and to tailor personalised treatment plans for these patients.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials","authors":"Cristian Udovicich ,&nbsp;Patrick Cheung ,&nbsp;William Chu ,&nbsp;Hans Chung ,&nbsp;Jay Detsky ,&nbsp;Stanley Liu ,&nbsp;Gerard Morton ,&nbsp;Ewa Szumacher ,&nbsp;Chia-Lin Tseng ,&nbsp;Danny Vesprini ,&nbsp;Wee Loon Ong ,&nbsp;Thomas Kennedy ,&nbsp;Melanie Davidson ,&nbsp;Ananth Ravi ,&nbsp;Merrylee McGuffin ,&nbsp;Liying Zhang ,&nbsp;Alexandre Mamedov ,&nbsp;Andrea Deabreu ,&nbsp;Meghan Kulasingham-Poon ,&nbsp;Andrew Loblaw","doi":"10.1016/j.euo.2024.12.015","DOIUrl":"10.1016/j.euo.2024.12.015","url":null,"abstract":"<div><h3>Background and objective</h3><div>Recent randomized controlled trials have demonstrated the efficacy of five-fraction stereotactic body radiotherapy (5F-SBRT) for prostate cancer (PC), but there is no comparative evidence for fewer fractions. We compare outcomes of prostate two-fraction SBRT (2F-SBRT) and 5F-SBRT using prospective data for patients with intermediate-risk (IR) PC.</div></div><div><h3>Methods</h3><div>This meta-analysis of individual patient data evaluated IR-PC from four prospective trials of prostate SBRT (two trials each of 2F- and 5F-SBRT). The primary endpoint was the cumulative incidence of biochemical failure (BCF). Secondary endpoints included the cumulative incidence of distant metastases (DM) and patient-reported quality of life (QoL).</div></div><div><h3>Key findings and limitations</h3><div>Of the 199 patients meeting the eligibility criteria, 143 (72%) were in the 5F-SBRT group and 56 (28%) were in the 2F-SBRT group. Median follow-up was 9.4 years. There was no significant difference in BCF with a 5-year cumulative incidence of 3.6% (95% CI 0–8.6%) in the 2F-SBRT group and 6.0% (95% CI 1.8–10.2%) in the 5F-SBRT group (<em>p</em> = 0.73). There was no significant difference in DM incidence. We found no differences in acute and late urinary or bowel QoL. Limitations include the non-randomized comparison.</div></div><div><h3>Conclusions and clinical implications</h3><div>We report the first prospective comparison of prostate 2F-SBRT and 5F-SBRT. We found no significant difference in efficacy, or in urinary or bowel QoL. This meta-analysis further encourages the potential of 2F-SBRT to be a standard-of-care option for IR PC.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Pages 763-773"},"PeriodicalIF":8.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143187738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Ignacio Puche-Sanz, Ugo Giovanni Falagario, Giorgio Gandaglia, et al’s Letter to the Editor re: Evelien J.E. van Altena, Bernard H.E. Jansen, Marieke L. Korbee, et al. Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.09.015","authors":"Evelien J.E. van Altena ,&nbsp;Bernard H.E. Jansen ,&nbsp;André N. Vis","doi":"10.1016/j.euo.2025.01.011","DOIUrl":"10.1016/j.euo.2025.01.011","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Pages 854-855"},"PeriodicalIF":8.3,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Small Testicular Masses: A Delphi Consensus Study","authors":"Karl H. Pang ,&nbsp;Giuseppe Fallara ,&nbsp;João Lobo ,&nbsp;Hussain M. Alnajjar ,&nbsp;Vijay Sangar ,&nbsp;Conrad von Stempel ,&nbsp;Dean Y. Huang ,&nbsp;Arie Parnham ,&nbsp;Walter Cazzaniga ,&nbsp;Francesco Giganti ,&nbsp;Aiman Haider ,&nbsp;Ashwin Sachdeva ,&nbsp;Maarten Albersen ,&nbsp;Costi Alifrangis ,&nbsp;Marco Bandini ,&nbsp;Fabio Castiglione ,&nbsp;Hielke-Martijn De Vries ,&nbsp;Christian Fankhauser ,&nbsp;Daniel Heffernan Ho ,&nbsp;David Nicol ,&nbsp;Asif Muneer","doi":"10.1016/j.euo.2024.10.010","DOIUrl":"10.1016/j.euo.2024.10.010","url":null,"abstract":"<div><h3>Background and objective</h3><div>The majority of small testicular masses (STMs) are benign and therefore radical orchidectomy (RO) may represent overtreatment. In appropriately selected patients, surveillance or testis-sparing surgery (TSS) is an alternative option to preserve testicular function. Since there are no clear guidelines, we aimed to develop consensus recommendations on the management of STMs.</div></div><div><h3>Methods</h3><div>A four-round Delphi study was conducted by 24 experts representing multiple subspecialties to reach consensus. Consensus was defined as ≥75% of the participants scoring within the same 3-point grouping (1–3, disagree; 4–6, uncertain; 7–9, agree.). The first two rounds were survey based, the third round was an online meeting to discuss uncertainties from the first two rounds, and the fourth round was a review of the final consensus statements from rounds 1–3.</div></div><div><h3>Key findings and limitations</h3><div>The initial survey consisted of 126 statements. Following the four rounds of assessment, a list of 96 statements were produced, which focused on clinical and biochemical assessment, colour Doppler ultrasound (CDUS) characteristics, and management options including surveillance, RO, and TSS. Management should be personalised according to risk factors for testicular cancer, fertility status, uni- or bilateral tumours, status of the contralateral testis, and CDUS characteristics, with solid lesions displaying vascularity and hypoechogenicity being more suspicious for malignancy. The consensus statements are prone to a bias, and some may not reflect robust, randomised evidence.</div></div><div><h3>Conclusions and clinical implications</h3><div>The expert panel has produced consensus recommendations on the management of STMs, and TSS should be considered in patients with an STM. The recommendations could aid in the dissemination of best practice.</div></div><div><h3>Patient summary</h3><div>There are no clear guidelines on the management of small testicular masses. Excising the whole testicle (radical orchidectomy) with a small or an indeterminate mass may affect fertility and hormonal function. A panel of experts was formed, and consensus recommendations were developed on how to deal with small and indeterminate testicular masses, which include surveillance or testis-sparing surgery.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 152-163"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related Quality of Life Assessment in Renal Cell Cancer: A Scoping Review","authors":"Franziska Gross ,&nbsp;Ida Marie Lind Rasmussen ,&nbsp;Elisabeth Grov Beisland ,&nbsp;Gøril Tvedten Jorem ,&nbsp;Christian Beisland ,&nbsp;Helle Pappot ,&nbsp;Juan Ignacio Arraras ,&nbsp;Madeline Pe ,&nbsp;Bernhard Holzner ,&nbsp;Lisa M. Wintner ,&nbsp;EORTC Quality of Life Group","doi":"10.1016/j.euo.2024.09.007","DOIUrl":"10.1016/j.euo.2024.09.007","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background and objective&lt;/h3&gt;&lt;div&gt;In oncology, patient-reported outcome measures (PROMs) capturing health-related quality of life (HRQOL) play an increasing role in clinical trials, drug approval, and policy making. This scoping review aimed to identify and elaborate on HRQOL-focussed PROMs used in renal cell cancer (RCC) clinical trials.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;MEDLINE, Web of Science, PsychINFO, Academic Search Elite, CINAHL, Embase, and the Cochrane Library were searched systematically for original peer-reviewed articles on clinical trials including RCC patients and using PROMs, published between 1950 and 2023. Prespecified trial characteristics and information on the PROMs used were extracted. Frequencies and proportions of categorical data, and ranges and medians of continuous variables were calculated.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Key findings and limitations&lt;/h3&gt;&lt;div&gt;Of the 48 unique studies included, the majority followed a randomised controlled design (34, 71%) and evaluated systemic treatments (38, 79%). The trials used 27 different PROMs (max = 6, median = 2), of which only 4 (15%) were developed specifically for kidney cancer patients. Of the trials, 46% did not use any RCC-specific PROM. European Quality of Life—5 Dimensions (EQ-5D), European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), Functional Assessment of Cancer Therapy Kidney Symptom Index (FKSI) —15/19-item version, FKSI—Disease Related Symptoms, and Functional Assessment of Cancer Therapy—General (FACT-G) were the most frequently used questionnaires, with pain, ability to work, fatigue, worry, and sleep quality being the most commonly assessed issues.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions and clinical implications&lt;/h3&gt;&lt;div&gt;A variety of PROMs are used in RCC patients, hindering interpretability across trials. The PROMs used differ in terms of both the domains assessed and how the issues are translated into questionnaire items. Though RCC-specific PROMs exist, these have flaws in terms of relevance to patients. To answer predefined relevant HRQOL research questions, revised RCC-specific PROMs and standardisation of their integration into clinical trials are warranted.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patient summary&lt;/h3&gt;&lt;div&gt;Researchers are more and more interested in the health-related quality of life of kidney cancer patients and use questionnaires to measure it. This review shows that there are many different health-related quality of life questionnaires that are used in different combinations in clinical trials for kidney cancer patients. This makes it very difficult to compare these study results and draw reliable conclusions for the actual clinical treatment. It was even found that some of the questionnaires used do not capture things that patients actually consider important (eg, emotional issues such as dealing with thoughts about cancer and depression). Therefore, more work needs to be done to develop questionnaires t","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 201-212"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}